MX361458B - Compuestos de pirimido-piridazinona y uso de los mismos. - Google Patents

Compuestos de pirimido-piridazinona y uso de los mismos.

Info

Publication number
MX361458B
MX361458B MX2014002112A MX2014002112A MX361458B MX 361458 B MX361458 B MX 361458B MX 2014002112 A MX2014002112 A MX 2014002112A MX 2014002112 A MX2014002112 A MX 2014002112A MX 361458 B MX361458 B MX 361458B
Authority
MX
Mexico
Prior art keywords
compounds
pyrimido
pyridazinone compounds
pyridazinone
novel pyrimido
Prior art date
Application number
MX2014002112A
Other languages
English (en)
Other versions
MX2014002112A (es
Inventor
Aranapakam Venkatesan
Roger Astbury Smith
Subramanya Hosahalli
Vijay Potluri
Sunil Kumar Panigrahi
Vishnu Basetti
Karunasree Kuntu
Original Assignee
Asana Biosciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asana Biosciences Llc filed Critical Asana Biosciences Llc
Publication of MX2014002112A publication Critical patent/MX2014002112A/es
Publication of MX361458B publication Critical patent/MX361458B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Abstract

La presente solicitud proporciona novedosos compuestos de dirimido-piridazinona y métodos para preparar y usar estos compuestos; estos compuestos son útiles en el tratamiento de la inflamación en pacientes por medio de la administración de uno o más de los compuestos a un paciente; en una modalidad, el novedoso compuesto de dirimido-piridazinona es de la fórmula (I) y R1 y R2 son como se definen en la presente.
MX2014002112A 2011-08-23 2012-08-23 Compuestos de pirimido-piridazinona y uso de los mismos. MX361458B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161526525P 2011-08-23 2011-08-23
PCT/US2012/051980 WO2013028818A1 (en) 2011-08-23 2012-08-23 Pyrimido- pyridazinone compounds and use thereof

Publications (2)

Publication Number Publication Date
MX2014002112A MX2014002112A (es) 2014-09-25
MX361458B true MX361458B (es) 2018-12-06

Family

ID=46829884

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002112A MX361458B (es) 2011-08-23 2012-08-23 Compuestos de pirimido-piridazinona y uso de los mismos.

Country Status (13)

Country Link
US (5) US8729079B2 (es)
EP (4) EP3404029A3 (es)
JP (1) JP5993010B2 (es)
CN (2) CN103974955B (es)
BR (1) BR112014003981A2 (es)
CA (1) CA2846187A1 (es)
DK (2) DK3392252T3 (es)
ES (1) ES2690971T3 (es)
FI (1) FI3392252T3 (es)
IL (1) IL231082A (es)
MX (1) MX361458B (es)
PL (1) PL2748166T3 (es)
WO (1) WO2013028818A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2690971T3 (es) * 2011-08-23 2018-11-23 Asana Biosciences, Llc Compuestos pirimido-piridazinona y uso de los mismos
AR106830A1 (es) * 2015-12-04 2018-02-21 Asana Biosciences Llc Usos de piridazinonas para tratar el cáncer
WO2018187294A1 (en) * 2017-04-03 2018-10-11 Asana Biosciences, Llc Pyrimido-pyridazinone compound combinations, methods, kits and formulations thereof
CA3060316A1 (en) * 2017-04-28 2018-11-01 Asana Biosciences, Llc Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
CN111961035B (zh) * 2019-05-20 2022-11-01 南京科技职业学院 一类含有羟基异喹啉类结构的化合物、药物组合物以及其应用
WO2021027943A1 (zh) * 2019-08-14 2021-02-18 正大天晴药业集团南京顺欣制药有限公司 哒嗪酮并嘧啶类衍生物及其医药用途
CN113583026A (zh) * 2020-04-30 2021-11-02 杭州英创医药科技有限公司 一类含有稠合三环结构的化合物
TW202202498A (zh) * 2020-07-01 2022-01-16 大陸商四川海思科製藥有限公司 一種並環雜環衍生物及其在醫藥上的應用
WO2023122662A1 (en) * 2021-12-22 2023-06-29 The Regents Of The University Of California Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase
WO2023164024A1 (en) * 2022-02-23 2023-08-31 Teva Pharmaceuticals International Gmbh Solid state forms of gusacitinib
WO2023192989A2 (en) * 2022-04-01 2023-10-05 Azkarra Therapeutics, Inc. Phthalazinone compounds as parp7 inhibitors

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE756508A (fr) * 1969-09-24 1971-03-01 Takeda Chemical Industries Ltd Derives de pyrimidopyridazine
CA1004223A (en) * 1972-05-12 1977-01-25 Theodor Denzel Amino derivatives of pyrido(2,3-d)pyridazine carboxylic acids and esters
JPS4948695U (es) 1972-07-29 1974-04-27
JPS50101387A (es) * 1974-01-16 1975-08-11
CA1052046A (en) 1974-01-21 1979-04-03 American Cyanamid Company Unsymmetrically substituted 1,4-dioxane-2,5-diones
US5369086A (en) 1993-04-28 1994-11-29 Zeneca Limited N-benzotriazoles
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
JPH0948695A (ja) 1995-08-02 1997-02-18 Toshiba Ceramics Co Ltd シリコン単結晶の製造方法
JP2002504550A (ja) 1998-02-25 2002-02-12 ファルマシア・アンド・アップジョン・カンパニー 抗微生物剤として有用な置換アミノメチルイソオキサゾリン誘導体
OA11674A (en) 1998-11-10 2005-01-12 Janssen Pharmaceutica Nv HIV Replication inhibiting pyrimidines.
CA2422054C (en) * 2000-09-22 2011-01-11 Akzo Nobel Nv Bicyclic heteroaromatic compounds
CN1649848A (zh) 2001-04-30 2005-08-03 葛兰素集团有限公司 作为促肾上腺皮质激素释放因子(crf)拮抗剂的稠合嘧啶衍生物
AU2003212634A1 (en) 2002-03-11 2003-09-22 Zetiq Technologies Ltd. Compounds useful in the treatment of cancer
US7517886B2 (en) 2002-07-29 2009-04-14 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
CN1894234A (zh) 2003-03-25 2007-01-10 武田药品工业株式会社 二肽基肽酶抑制剂
CN102358738A (zh) 2003-07-30 2012-02-22 里格尔药品股份有限公司 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途
WO2005080377A1 (ja) 2004-02-20 2005-09-01 Kirin Beer Kabushiki Kaisha TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
TW200626574A (en) 2004-09-30 2006-08-01 Tibotec Pharm Ltd HIV inhibiting 5-heterocyclyl pyrimidines
PL1830869T3 (pl) 2004-12-24 2013-11-29 Novartis Ag Sposób leczenia lub profilaktyki
MX2007011850A (es) 2005-03-25 2007-10-03 Tibotec Pharm Ltd Inhibidores heterobiciclicos de virus de hepatitis c.
CN101189234B (zh) 2005-03-25 2011-08-17 泰博特克药品有限公司 Hcv的杂二环抑制剂
KR20080000584A (ko) 2005-04-29 2008-01-02 얀센 파마슈티카 엔.브이. 카나비노이드 수용체 길항제로서의 벤조트리아졸 유도체
EP1970373A1 (en) * 2005-12-02 2008-09-17 Mitsubishi Tanabe Pharma Corporation Alicyclic heterocyclic compound
US20070161670A1 (en) 2006-01-09 2007-07-12 Bristol-Myers Squibb Company Process for the preparation of substituted heterocycles
WO2007125405A2 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
GB0625196D0 (en) 2006-12-18 2007-01-24 7Tm Pharma As Modulators of cannabinoid receptor
HUE027641T2 (en) * 2006-12-28 2016-11-28 Abbvie Inc Poly (ADP-ribose) polymerase inhibitors
EA018441B1 (ru) 2007-03-14 2013-08-30 ЭКСЕЛИКСИС ПАТЕНТ КОМПАНИ ЭлЭлСи Ингибиторы пути хеджхога
TW200942537A (en) 2008-02-01 2009-10-16 Irm Llc Compounds and compositions as kinase inhibitors
CA2737217A1 (en) * 2008-09-30 2010-04-08 Astrazeneca Ab Heterocyclic jak kinase inhibitors
TW201016676A (en) 2008-10-03 2010-05-01 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
US20100216827A1 (en) 2008-10-21 2010-08-26 Metabolex, Inc. Aryl gpr120 receptor agonists and uses thereof
CA2779105C (en) * 2009-10-29 2016-08-16 Hong Woo Kim Kinase inhibitors
TW201130852A (en) * 2009-12-23 2011-09-16 Abbott Lab Novel thienopyrrole compounds
US8440662B2 (en) 2010-10-31 2013-05-14 Endo Pharmaceuticals, Inc. Substituted quinazoline and pyrido-pyrimidine derivatives
ES2690971T3 (es) * 2011-08-23 2018-11-23 Asana Biosciences, Llc Compuestos pirimido-piridazinona y uso de los mismos
WO2014022728A1 (en) 2012-08-02 2014-02-06 Endo Pharmaceuticals, Inc Substituted 5 - (quinazolin - 2 - yl) pyrimidin- 2 -amine derivatives useful as pi3k/mtor inhibitors for the treatment of cancer
AR106830A1 (es) * 2015-12-04 2018-02-21 Asana Biosciences Llc Usos de piridazinonas para tratar el cáncer
CA3060316A1 (en) * 2017-04-28 2018-11-01 Asana Biosciences, Llc Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient

Also Published As

Publication number Publication date
EP3392252A1 (en) 2018-10-24
PL2748166T3 (pl) 2019-05-31
US8729079B2 (en) 2014-05-20
JP5993010B2 (ja) 2016-09-14
US10647720B2 (en) 2020-05-12
US20130053346A1 (en) 2013-02-28
US20200190095A1 (en) 2020-06-18
EP2748166A1 (en) 2014-07-02
IL231082A0 (en) 2014-03-31
EP2748166B1 (en) 2018-07-11
DK3392252T3 (da) 2024-01-08
WO2013028818A1 (en) 2013-02-28
WO2013028818A8 (en) 2013-09-19
JP2014524475A (ja) 2014-09-22
FI3392252T3 (fi) 2024-01-08
CN108707151A (zh) 2018-10-26
US20160257691A1 (en) 2016-09-08
EP3404029A3 (en) 2018-12-12
MX2014002112A (es) 2014-09-25
EP3392252B1 (en) 2023-10-04
US20140221315A1 (en) 2014-08-07
US20190092779A1 (en) 2019-03-28
CA2846187A1 (en) 2013-02-28
DK2748166T3 (en) 2018-10-29
US10183944B2 (en) 2019-01-22
EP3404029A2 (en) 2018-11-21
ES2690971T3 (es) 2018-11-23
IL231082A (en) 2016-09-29
CN108707151B (zh) 2022-06-03
BR112014003981A2 (pt) 2017-03-07
EP4327886A2 (en) 2024-02-28
CN103974955A (zh) 2014-08-06
CN103974955B (zh) 2018-06-19
US9382277B2 (en) 2016-07-05

Similar Documents

Publication Publication Date Title
MX2014002112A (es) Compuestos de pirimido-piridazinona y uso de los mismos.
AU2016202535B2 (en) Fused heterocyclic compounds as sodium channel modulators
MY184306A (en) Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
MX338916B (es) Oxazepinas como moduladores del canal de iones.
NZ709211A (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
NZ609309A (en) Redox drug derivatives
EA201590453A1 (ru) Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b
MX339149B (es) Inhibidores de replicacion del virus de influenza.
EA201301154A1 (ru) Разветвленные производные 3-фенилпропионовой кислоты и их применение
EA201390381A1 (ru) Триазиноксадиазолы
IN2014MN01755A (es)
EA201490647A1 (ru) Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции
BR112012023021A2 (pt) compostos de indazol e seus usos
MX2013006846A (es) Inhibidores de la replicacion de los virus de la influenza.
MA33939B1 (fr) 5-alcynyl-pyrimidines
MX2014008021A (es) Compuestos de fenil carbamato para usarse en aliviar o tratar el dolor.
MX2015003021A (es) Derivados de acido glicirretinico y metodos de uso de los mismos.
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
MX348961B (es) Compuestos de aminoindano y su uso en el tratamiento del dolor.
UA107562C2 (uk) Спосіб лікування псоріазу
MX364400B (es) Compuestos de tetraciclina.
JO3063B1 (ar) مركب مبتكر وطرق لانتاجه
MX342153B (es) Compuestos para el tratamiento y profilaxis de enfermedad por el virus sincitial respiratorio.
TN2015000095A1 (en) Macrolide derivatives, preparation thereof and therapeutic use thereof
MX2013006670A (es) Derivado de 2-carboxamida-4-piperazinil-benzofurano.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ASANA BIOSCIENCES, LLC

FG Grant or registration